

Joop A M J L Janssen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6875773/publications.pdf>

Version: 2024-02-01

148
papers

8,211
citations

44069

48
h-index

51608

86
g-index

151
all docs

151
docs citations

151
times ranked

8469
citing authors

#	ARTICLE	IF	CITATIONS
1	Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation.. Journal of Clinical Investigation, 1987, 79, 1635-1641.	8.2	365
2	A Polymorphism in the Gene for IGF-I. Diabetes, 2001, 50, 637-642.	0.6	338
3	High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control. Diabetes Care, 2013, 36, 1619-1628.	8.6	309
4	A Polymorphism in the Glucocorticoid Receptor Gene, Which Decreases Sensitivity to Glucocorticoids In Vivo, Is Associated With Low Insulin and Cholesterol Levels. Diabetes, 2002, 51, 3128-3134.	0.6	294
5	Identification of the <i>Bcl</i> polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids <i>in vivo</i> and body mass index. Clinical Endocrinology, 2003, 59, 585-592.	2.4	279
6	Ghrelin Stimulates, Whereas Des-Octanoyl Ghrelin Inhibits, Glucose Output by Primary Hepatocytes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1055-1060.	3.6	269
7	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. Annals of Internal Medicine, 2008, 149, 461.	3.9	263
8	Administration of Acylated Ghrelin Reduces Insulin Sensitivity, Whereas the Combination of Acylated Plus Unacylated Ghrelin Strongly Improves Insulin Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5035-5042.	3.6	224
9	Serum Total IGF-I, Free IGF-I, and IGFBP-1 Levels in an Elderly Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 277-282.	2.4	223
10	Endogenous Hormones and Carotid Atherosclerosis in Elderly Men. American Journal of Epidemiology, 2003, 157, 25-31.	3.4	221
11	Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet, The, 2005, 365, 1644-1646.	13.7	214
12	Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet, The, 2002, 359, 1036-1037.	13.7	191
13	Circulating IgGs May Modulate IGF-I Receptor Stimulating Activity in a Subset of Patients With Graves' Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 769-776.	3.6	161
14	Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3853-3859.	3.6	153
15	Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4598-4601.	3.6	146
16	Ghrelin drives GH secretion during fasting in man. European Journal of Endocrinology, 2002, 146, 203-207.	3.7	135
17	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research, 2016, 76, 2288-2300.	0.9	117
18	Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. Endocrine Reviews, 2019, 40, 236-267.	20.1	117

#	ARTICLE	IF	CITATIONS
19	Retinal Vessel Diameters and Risk of Impaired Fasting Glucose or Diabetes. <i>Diabetes</i> , 2006, 55, 506-510.	0.6	114
20	Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. <i>European Journal of Endocrinology</i> , 2009, 160, 529-533.	3.7	110
21	Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. <i>European Journal of Endocrinology</i> , 2001, 145, 711-716.	3.7	105
22	Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3644-3652.	3.6	103
23	A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 289, E75-E81.	3.5	98
24	Hemodynamic and Biochemical Effects of the AT 1 Receptor Antagonist Irbesartan in Hypertension. <i>Hypertension</i> , 1995, 25, 22-29.	2.7	97
25	Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 478-481.	3.6	92
26	Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6480-6489.	3.6	91
27	Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. <i>American Journal of Medicine</i> , 2004, 117, 158-162.	1.5	90
28	Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7797.	4.1	88
29	Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels. <i>Clinical Endocrinology</i> , 1998, 48, 471-478.	2.4	83
30	A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. <i>European Journal of Endocrinology</i> , 2003, 148, 171-175.	3.7	83
31	Insulin and its analogues and their affinities for the IGF1 receptor. <i>Endocrine-Related Cancer</i> , 2012, 19, F63-F75.	3.1	83
32	Genomewide meta-analysis identifies loci associated with <scp>IGF</scp> and <scp>IGFBP</scp> levels with impact on age-related traits. <i>Aging Cell</i> , 2016, 15, 811-824.	6.7	83
33	The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4942-4952.	3.6	81
34	Low Circulating Insulin-Like Growth Factor I Bioactivity in Elderly Men Is Associated with Increased Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2515-2522.	3.6	78
35	Low circulating IGF-I bioactivity is associated with human longevity: Findings in centenarians' offspring. <i>Aging</i> , 2012, 4, 580-589.	3.1	78
36	Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. <i>Clinical Endocrinology</i> , 2000, 52, 1-9.	2.4	76

#	ARTICLE	IF	CITATIONS
37	Very long-term sequelae of craniopharyngioma. <i>European Journal of Endocrinology</i> , 2017, 176, 755-767.	3.7	76
38	A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. <i>Clinical Endocrinology</i> , 2004, 61, 195-203.	2.4	74
39	Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. <i>Molecular and Cellular Endocrinology</i> , 2006, 251, 103-111.	3.2	73
40	The Influence of an Insulin-Like Growth Factor I Gene Promoter Polymorphism on Hip Bone Geometry and the Risk of Nonvertebral Fracture in the Elderly: The Rotterdam Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1280-1290.	2.8	64
41	Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E697-E704.	3.5	64
42	The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?. <i>European Journal of Endocrinology</i> , 2002, 146, 467-477.	3.7	63
43	Normal Values of Circulating Insulin-Like Growth Factor-I Bioactivity in the Healthy Population: Comparison with Five Widely Used IGF-I Immunoassays. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2539-2545.	3.6	58
44	Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 586-595.	3.6	58
45	Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. <i>European Journal of Endocrinology</i> , 1998, 138, 627-632.	3.7	56
46	Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 (IGFBP-1), and IGFBP-3 and Their Relationships to the Presence of Diabetic Retinopathy and Glomerular Hyperfiltration in Insulin-Dependent Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2809-2815.	3.6	55
47	A Polymorphism in Type I Deiodinase Is Associated with Circulating Free Insulin-Like Growth Factor I Levels and Body Composition in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 256-263.	3.6	50
48	Polymorphism in the Promoter Region of the Insulin-like Growth Factor I Gene Is Related to Carotid Intima-Media Thickness and Aortic Pulse Wave Velocity in Subjects With Hypertension. <i>Stroke</i> , 2003, 34, 1623-1627.	2.0	49
49	IGF-IR Targeted Therapy: Past, Present and Future. <i>Frontiers in Endocrinology</i> , 2014, 5, 224.	3.5	49
50	Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case-control study with 2 years of follow-up. <i>International Journal of Obesity</i> , 2017, 41, 210-216.	3.4	45
51	IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. <i>Clinical Endocrinology</i> , 1995, 43, 501-505.	2.4	42
52	Circulating Free Insulin-Like Growth Factor (IGF)-I, Total IGF-I, and IGF Binding Protein-3 Levels Do Not Predict the Future Risk to Develop Prostate Cancer: Results of a Case-Control Study Involving 201 Patients within a Population-Based Screening with a 4-Year Interval. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4391-4396.	3.6	42
53	Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. <i>European Journal of Endocrinology</i> , 2005, 153, 67-71.	3.7	42
54	Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study. <i>European Journal of Endocrinology</i> , 2018, 178, 93-102.	3.7	42

#	ARTICLE	IF	CITATIONS
55	The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. <i>European Journal of Endocrinology</i> , 2018, 178, 11-22.	3.7	41
56	A Prospective Study on Circulating Insulin-Like Growth Factor I (IGF-I), IGF-Binding Proteins, and Cognitive Function in the Elderly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4551-4555.	3.6	41
57	Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. <i>European Journal of Endocrinology</i> , 2018, 179, 269-277.	3.7	38
58	Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). <i>American Journal of Cardiology</i> , 2004, 94, 384-386.	1.6	37
59	Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 915-924.	3.6	37
60	The "bio-assay"™ quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. <i>European Journal of Endocrinology</i> , 2005, 152, 217-224.	3.7	36
61	The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men. <i>Clinical Endocrinology</i> , 2007, 66, 808-815.	2.4	35
62	IGF-I Bioactivity in an Elderly Population: Relation to Insulin Sensitivity, Insulin Levels, and the Metabolic Syndrome. <i>Diabetes</i> , 2010, 59, 505-508.	0.6	35
63	Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis?. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 313-315.	3.3	32
64	How to Position Pasireotide LAR Treatment in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1978-1988.	3.6	32
65	Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2016, 7, 167.	3.5	31
66	Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 478-481.	3.6	31
67	Serum Free and Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 and Insulin-Like Growth Factor Binding Protein-3 Levels in Healthy Elderly Individuals. <i>Gerontology</i> , 1998, 44, 277-280.	2.8	30
68	Impact of Physical Exercise on Endocrine Aging. <i>Frontiers of Hormone Research</i> , 2016, 47, 68-81.	1.0	30
69	Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency. <i>Clinical Endocrinology</i> , 2002, 56, 765-771.	2.4	29
70	Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E559-E566.	3.5	27
71	The acute effect of dexamethasone on plasma leptin concentrations and the relationships between fasting leptin, the IGF/IGFBP system, dehydroepiandrosterone, androstenedione and testosterone in an elderly population. <i>Clinical Endocrinology</i> , 1998, 48, 621-626.	2.4	26
72	Lack of associations between serum leptin, a polymorphism in the gene for the β 2-adrenergic receptor and glucose tolerance in the Dutch population.. <i>Clinical Endocrinology</i> , 1998, 49, 229-234.	2.4	26

#	ARTICLE	IF	CITATIONS
73	Acute Stress Response in Children with Meningococcal Sepsis: Important Differences in the Growth Hormone/Insulin-Like Growth Factor I Axis between Nonsurvivors and Survivors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3118-3124.	3.6	26
74	High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men. <i>European Journal of Endocrinology</i> , 2012, 167, 111-117.	3.7	25
75	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , 2014, 21, 601-613.	3.1	25
76	Insulin-Like Growth Factor-I Receptor Stimulating Activity is Associated with Dementia. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 137-142.	2.6	25
77	An IGF-I Gene Polymorphism Modifies the Risk of Diabetic Retinopathy. <i>Diabetes</i> , 2006, 55, 2387-2391.	0.6	24
78	Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. <i>Neuroendocrinology</i> , 2017, 105, 44-53.	2.5	24
79	Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 20.	3.4	24
80	New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations. <i>Cells</i> , 2020, 9, 862.	4.1	24
81	Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 588-594.	3.3	23
82	A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy. <i>Heart</i> , 2005, 91, 239-240.	2.9	23
83	IGF-I Bioactivity Might Reflect Different Aspects of Quality of Life Than Total IGF-I in GH-Deficient Patients During GH Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 761-768.	3.6	23
84	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. <i>Endocrine</i> , 2019, 64, 673-684.	2.3	23
85	Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. <i>Growth Hormone and IGF Research</i> , 2010, 20, 427-431.	1.1	21
86	Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. <i>Endocrine-Related Cancer</i> , 2016, 23, 727-737.	3.1	21
87	IGF-I and Longevity. <i>Hormone Research in Paediatrics</i> , 2004, 62, 104-109.	1.8	20
88	Insulin-Like Growth Factor I: Pros and Cons of a Bioassay. <i>Hormone Research in Paediatrics</i> , 2011, 76, 106-110.	1.8	20
89	Heterophilic antibodies may be a cause of falsely low total IGF1 levels. <i>European Journal of Endocrinology</i> , 2009, 161, 561-565.	3.7	19
90	Effect of Intensive Insulin Therapy on the Somatotrophic Axis of Critically Ill Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2558-2566.	3.6	19

#	ARTICLE	IF	CITATIONS
91	IGF-I Bioactivity Better Reflects Growth Hormone Deficiency than Total IGF-I. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2248-2254.	3.6	19
92	Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling. Diabetes, 2013, 62, 2539-2544.	0.6	19
93	The Introduction of the IDS-iSYS Total IGF-1 Assay May Have Far-Reaching Consequences for Diagnosis and Treatment of GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 309-316.	3.6	19
94	An Insulin-Like Growth Factor-I Promoter Polymorphism Is Associated With Increased Mortality in Subjects With Myocardial Infarction in an Elderly Caucasian Population. American Journal of Cardiology, 2006, 97, 1274-1276.	1.6	18
95	Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I. European Journal of Endocrinology, 2006, 155, 293-296.	3.7	18
96	Intravenous Glucose Administration in Fasting Rats Has Differential Effects on Acylated and Unacylated Ghrelin in the Portal and Systemic Circulation: A Comparison between Portal and Peripheral Concentrations in Anesthetized Rats. Endocrinology, 2007, 148, 5278-5287.	2.8	18
97	Blockade of the Growth Hormone (GH) Receptor Unmasks Rapid GH-Releasing Peptide-6-Mediated Tissue-Specific Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 590-593.	3.6	18
98	The β -Adducin Gene Is Associated With Macrovascular Complications and Mortality in Patients With Type 2 Diabetes. Diabetes, 2006, 55, 2922-2927.	0.6	17
99	It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, S1-S12.	3.6	17
100	Advantages and disadvantages of GH/IGF-I combination treatment. Reviews in Endocrine and Metabolic Disorders, 2009, 10, 157-162.	5.7	16
101	Central ghrelin production does not substantially contribute to systemic ghrelin concentrations: a study in two subjects with active acromegaly. European Journal of Endocrinology, 2002, 147, 195-199.	3.7	14
102	IGF-1 CA repeat variant and breast cancer risk in postmenopausal women. European Journal of Cancer, 2007, 43, 1718-1722.	2.8	14
103	Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia, 2012, 55, 1186-1194.	6.3	14
104	Insulin Analogs and Cancer: A Note of Caution. Frontiers in Endocrinology, 2014, 5, 79.	3.5	14
105	IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes. European Journal of Endocrinology, 2006, 155, 751-756.	3.7	13
106	Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes. Diabetes, 2007, 56, 1905-1912.	0.6	13
107	An Early Diagnostic Tool for Diabetic Peripheral Neuropathy in Rats. PLoS ONE, 2015, 10, e0126892.	2.5	13
108	Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-stimulated growth hormone secretion. Clinical Endocrinology, 2001, 55, 461-467.	2.4	12

#	ARTICLE	IF	CITATIONS
109	Insulin-like growth factor-I genotype and birthweight. <i>Lancet</i> , The, 2002, 360, 945-946.	13.7	12
110	In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life. <i>Endocrine Connections</i> , 2014, 3, 85-92.	1.9	12
111	Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. <i>European Journal of Endocrinology</i> , 2019, 181, 173-183.	3.7	12
112	The IGF-I/IGFBP system in congenital partial lipodystrophy. <i>Clinical Endocrinology</i> , 1998, 49, 465-473.	2.4	11
113	Insulin-like growth factor I receptors on blood cells: their relationship to circulating total and free IGF-I, IGFBP-1, IGFBP-3 and insulin levels in healthy subjects. <i>Growth Hormone and IGF Research</i> , 1998, 8, 47-54.	1.1	11
114	Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. <i>Endocrine Connections</i> , 2013, 2, 172-177.	1.9	11
115	Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells. <i>Neuroendocrinology</i> , 2016, 103, 815-825.	2.5	11
116	What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?. <i>European Journal of Endocrinology</i> , 2016, 174, 663-667.	3.7	11
117	Commentary: A polymorphic CA repeat in the promoter region of the insulin-like growth factor I (IGF-I) gene. <i>European Journal of Epidemiology</i> , 2002, 18, 191-194.	5.7	10
118	Is there a role of ghrelin in preventing catabolism?. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 400-403.	3.3	10
119	An insulin-like growth factor-I gene polymorphism modifies the risk of microalbuminuria in subjects with an abnormal glucose tolerance. <i>European Journal of Endocrinology</i> , 2006, 154, 715-721.	3.7	10
120	An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. <i>European Journal of Endocrinology</i> , 2007, 156, 83-90.	3.7	10
121	Response to Krieger et al. re: "TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis" (Thyroid 2017;27:746-747). <i>Thyroid</i> , 2017, 27, 1458-1459.	4.5	10
122	Soluble Klotho: a possible predictor of quality of life in acromegaly patients. <i>Endocrine</i> , 2020, 69, 165-174.	2.3	10
123	Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. <i>Cells</i> , 2021, 10, 383.	4.1	10
124	Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling. <i>Molecular and Cellular Endocrinology</i> , 2013, 365, 17-24.	3.2	9
125	There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 659-664.	3.3	8
126	Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms. <i>Transplantation Direct</i> , 2018, 4, e350.	1.6	8

#	ARTICLE	IF	CITATIONS
127	Disagreement in normative IGF levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency. <i>Clinical Endocrinology</i> , 2018, 88, 409-414.	2.4	8
128	The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease. <i>Growth Hormone and IGF Research</i> , 2019, 48-49, 16-28.	1.1	8
129	Mechanisms of putative IGF-I receptor resistance in active acromegaly. <i>Growth Hormone and IGF Research</i> , 2020, 52, 101319.	1.1	8
130	Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 940-946.	0.7	6
131	Potency of Full- Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. <i>PLoS ONE</i> , 2016, 11, e0150453.	2.5	6
132	Insulin-like growth factor-I and risk of breast cancer. <i>Lancet</i> , The, 1998, 352, 490.	13.7	5
133	The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. <i>Clinical Endocrinology</i> , 2006, 64, 203-208.	2.4	5
134	Absence or low IGF-I R expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection. <i>Journal of Surgical Oncology</i> , 2015, 111, 1047-1053.	1.7	5
135	IGF-I and the endocrinology of aging. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 5, 1-6.	1.4	5
136	Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults. <i>European Journal of Endocrinology</i> , 2015, 173, 119-127.	3.7	3
137	Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3814-3821.	3.6	3
138	Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins. <i>European Journal of Endocrinology</i> , 2018, 178, 153-161.	3.7	3
139	Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1397-e1407.	3.6	3
140	IFN- γ is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells. <i>American Journal of Cancer Research</i> , 2015, 5, 2035-46.	1.4	3
141	Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4626-e4637.	3.6	2
142	Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells. <i>Frontiers in Oncology</i> , 2021, 11, 645732.	2.8	2
143	Acute Effect of Pegvisomant on Cardiovascular Risk Markers in Healthy Men: Implications for the Pathogenesis of Atherosclerosis in GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5165-5171.	3.6	2
144	Diabetes Associated with Glucocorticoid Excess. <i>Frontiers in Diabetes</i> , 2014, , 22-33.	0.4	1

#	ARTICLE	IF	CITATIONS
145	Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors alone and in combination with the dual IGF1-R/INS-R antagonist OSI-906. Endocrine Abstracts, 0, , .	0.0	1
146	Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients. Journal of Endocrinological Investigation, 2012, 35, 372-7.	3.3	1
147	P108 Effect of intensive insulin therapy on the somatotrophic axis in critically ill children. Growth Hormone and IGF Research, 2010, 20, S80.	1.1	0
148	Efficacy and safety of switching to pasireotide LAR monotherapy or in combination with pegvisomant in acromegaly patients controlled with combination therapy of somatostatin analogues and pegvisomant (PAPE study): a prospective, open-label 48 week study. Endocrine Abstracts, 0, , .	0.0	0